To read the full story
Related Article
- Employee Sues Bayer Japan for Emotional Distress over Xarelto Scandal
March 19, 2019
- JPMA Reprimands Bayer over Side Effect Reporting Violation, Chides “Inappropriate” Promotion
October 20, 2017
- (Update) Bayer Told to Improve Practice over ADR Reporting Delays, Gets “Verbal Guidance” for Xarelto Survey Fuss
October 2, 2017
- Bayer Instruction Existed in Patient Info Acquisition, Sales Rep Tells Govt Panel
August 25, 2017
- Whistleblower Bayer Rep Raps “No Instruction” Finding in Xarelto Scandal Probe
July 21, 2017
- Probe Finds No HQ Instruction for Improper Patient Info Acquisition in Xarelto Surveys, Bayer Execs Take 3-Month Pay Cuts
July 18, 2017
- MHLW Orders Bayer Blanket Probe on Side Effect Reporting
May 30, 2017
- Bayer Fails to Report 12 Side Effect Cases for Xarelto, Scandal Probe Finds
May 29, 2017
REGULATORY
- Japan Pharma Subgroup Talks to Feed into Pricing, Budget Debates
November 16, 2026
- Japan Names 38 Top-Rated Generic Makers for Stable Supply
November 16, 2026
- Pharma Calls for Drug Price Hikes, Govt Purchases to Spur MCM Investment
November 16, 2026
- Stable Supply Drives Japan’s Generic Drug Delistings: Jiho Tally
November 16, 2026
- Optimal Use Guidelines Issued for Vyepti; Updates for Leqembi, Kisunla, Keytruda
November 13, 2026
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





